GHRH Receptor Splice Variant Drives Esophageal Cancer Growth Under Low Oxygen, Offering Drug Target
The GHRH receptor splice variant SV1 is activated by hypoxia in esophageal cancer and drives tumor progression through enhanced glycolysis, but can be reversed by GHRH-R antagonist MIA-602.
Quick Facts
What This Study Found
Hypoxia-elevated SV1 splice variant activates PFKM through the NF-κB pathway, enhancing glycolytic metabolism and promoting esophageal cancer progression. GHRH-R antagonist MIA-602 reversed these malignant effects by targeting SV1.
Key Numbers
SV1 variant expressed in ESCC; standard pGHRH-R absent; GHRH-R antagonists significantly suppressed tumor growth.
How They Did This
Esophageal squamous cell carcinoma cell models with hypoxia exposure, signaling pathway analysis (NF-κB, PFKM), metabolic profiling, and in vivo validation. MIA-602 treatment tested against SV1-driven tumor progression.
Why This Research Matters
This study explains a longstanding puzzle — why GHRH-R antagonists work against cancers that don't express the standard receptor — and identifies SV1 as the actual therapeutic target, potentially expanding the use of these drugs to more cancer types.
The Bigger Picture
Understanding which receptor variants mediate drug effects is crucial for expanding cancer therapy options. The SV1 target discovery could help identify which patients are most likely to benefit from GHRH-R antagonist therapy across multiple cancer types.
What This Study Doesn't Tell Us
Focused on esophageal squamous cell carcinoma; generalizability to other cancer types expressing SV1 needs validation. MIA-602 is an experimental compound not yet in clinical use.
Questions This Raises
- ?Is SV1 expression a useful biomarker for selecting patients likely to respond to GHRH-R antagonists?
- ?Do other cancers that respond to GHRH-R antagonists also rely on the SV1 pathway?
- ?How does the SV1-targeting mechanism of MIA-602 differ from its action on the standard GHRH receptor?
Trust & Context
- Key Stat:
- SV1 GHRH receptor splice variant identified as the actual target of GHRH-R antagonists in cancers without standard receptor
- Evidence Grade:
- Combined in vitro and in vivo evidence with clear mechanistic pathway identified. Pre-clinical stage with an experimental antagonist compound.
- Study Age:
- Published in 2020. GHRH-R antagonist research continues with interest in targeting splice variants across cancer types.
- Original Title:
- Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target.
- Published In:
- Proceedings of the National Academy of Sciences of the United States of America, 117(12), 6726-6732 (2020)
- Authors:
- Xiong, Xiao, Ke, Xiurong(2), Wang, Lu(6), Yao, Zhimeng, Guo, Yi, Zhang, Xianyang, Chen, Yuping, Pang, Chi Pui, Schally, Andrew V, Zhang, Hao
- Database ID:
- RPEP-05207
Evidence Hierarchy
Frequently Asked Questions
What is a splice variant?
A splice variant is an alternative version of a protein produced when the gene's instructions are read differently, resulting in a slightly modified protein with potentially different functions.
Why does low oxygen promote cancer growth?
Tumors often outgrow their blood supply, creating low-oxygen (hypoxic) zones. Cancer cells adapt by switching to alternative metabolic pathways and activating genes that promote survival and spread.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05207APA
Xiong, Xiao; Ke, Xiurong; Wang, Lu; Yao, Zhimeng; Guo, Yi; Zhang, Xianyang; Chen, Yuping; Pang, Chi Pui; Schally, Andrew V; Zhang, Hao. (2020). Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target.. Proceedings of the National Academy of Sciences of the United States of America, 117(12), 6726-6732. https://doi.org/10.1073/pnas.1913433117
MLA
Xiong, Xiao, et al. "Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target.." Proceedings of the National Academy of Sciences of the United States of America, 2020. https://doi.org/10.1073/pnas.1913433117
RethinkPeptides
RethinkPeptides Research Database. "Splice variant of growth hormone-releasing hormone receptor ..." RPEP-05207. Retrieved from https://rethinkpeptides.com/research/xiong-2020-splice-variant-of-growth
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.